<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>clinical trials | Dominic Magirr</title>
    <link>/categories/clinical-trials/</link>
      <atom:link href="/categories/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    <description>clinical trials</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Sat, 12 Sep 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/icon-192.png</url>
      <title>clinical trials</title>
      <link>/categories/clinical-trials/</link>
    </image>
    
    <item>
      <title>Adjusting for covariates under non-proportional hazards</title>
      <link>/post/adjusting-for-covariates-under-non-proportional-hazards/</link>
      <pubDate>Sat, 12 Sep 2020 00:00:00 +0000</pubDate>
      <guid>/post/adjusting-for-covariates-under-non-proportional-hazards/</guid>
      <description>


&lt;p&gt;I’ve written a lot recently about &lt;a href=&#34;../../post/non-proportional-hazards-in-immuno-oncology-is-an-old-perspective-needed&#34;&gt;non-proportional hazards in immuno-oncology&lt;/a&gt;. One aspect that I have unfortunately overlooked is covariate adjustment. Perhaps this is because it’s so easy to work with &lt;a href=&#34;../../post/extract-patient-level-data-from-a-kaplan-meier-plot&#34;&gt;extracted data from published Kaplan-Meier plots&lt;/a&gt;, where the covariate data is not available. But we know from &lt;a href=&#34;https://www.jstor.org/stable/2531154&#34;&gt;theoretical&lt;/a&gt; and &lt;a href=&#34;https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-139&#34;&gt;empirical&lt;/a&gt; work that covariate adjustment can lead to big increases in power, and perhaps this is equally important or even more important than the power gains from using a weighted log-rank test to match the anticipated non-proportional hazards. To investigate this, we would need access to immuno-oncology RCT data. In general this is not so easy, but fortunately there’s &lt;a href=&#34;https://www.nature.com/articles/s41591-018-0134-3&#34;&gt;this article&lt;/a&gt; containing clinical data from two RCTs (OAK and POPLAR) comparing a checkpoint inhibitor (atezolizumab) versus chemotherapy.&lt;/p&gt;
&lt;p&gt;Gandara, D.R., Paul, S.M., Kowanetz, M. et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 24, 1441–1448 (2018). &lt;a href=&#34;https://doi.org/10.1038/s41591-018-0134-3&#34; class=&#34;uri&#34;&gt;https://doi.org/10.1038/s41591-018-0134-3&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;A number of covariates are provided but I will focus on baseline ECOG grade, which is a performance status indicator – a “0” means fully active; a “1” means restricted in physically strenuous activity. Generally, you would expect patients with lower ECOG status to have longer survival.&lt;/p&gt;
&lt;p&gt;Let’s have a look at the OAK data first…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;library(tidyverse)
library(survival)

## Here I&amp;#39;m loading my library locally...
devtools::load_all(&amp;quot;~/swlrt/&amp;quot;)

## ...but can also get it from github
#devtools::install_github(&amp;quot;dominicmagirr/swlrt&amp;quot;)

## read in the clinical data from the OAK study
## create a new column OS.EVENT which is the opposite
## of OS.CNSR

dat_oak &amp;lt;- readxl::read_excel(&amp;quot;41591_2018_134_MOESM3_ESM.xlsx&amp;quot;,
                              sheet = 3) %&amp;gt;% 
  select(PtID, ECOGGR, OS, OS.CNSR, TRT01P) %&amp;gt;%
  mutate(OS.EVENT = -1 * (OS.CNSR - 1))

## take a look at first few rows
head(dat_oak)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## # A tibble: 6 x 6
##    PtID ECOGGR    OS OS.CNSR TRT01P    OS.EVENT
##   &amp;lt;dbl&amp;gt;  &amp;lt;dbl&amp;gt; &amp;lt;dbl&amp;gt;   &amp;lt;dbl&amp;gt; &amp;lt;chr&amp;gt;        &amp;lt;dbl&amp;gt;
## 1   318      1  5.19       0 Docetaxel        1
## 2  1088      0  4.83       0 Docetaxel        1
## 3   345      1  1.94       0 Docetaxel        1
## 4   588      0 24.6        1 Docetaxel        0
## 5   306      1  5.98       0 MPDL3280A        1
## 6   718      1 19.2        1 Docetaxel        0&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;It’s standard fare for surival analysis. Let’s first make a Kaplan-Meier plot and fit a Cox model based only on treatment…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;km_oak &amp;lt;- survfit(Surv(OS, OS.EVENT) ~ TRT01P,
                  data = dat_oak)

survminer::ggsurvplot(km_oak, 
                      data = dat_oak, 
                      risk.table = TRUE, 
                      break.x.by = 6,
                      legend.title = &amp;quot;&amp;quot;,
                      xlab = &amp;quot;Time (months)&amp;quot;,
                      ylab = &amp;quot;Overall survival&amp;quot;,
                      risk.table.fontsize = 4,
                      legend = c(0.8,0.8))&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;&lt;img src=&#34;../../post/2020-09-12-adjusting-for-covariates-under-non-proportional-hazards_files/figure-html/unnamed-chunk-2-1.png&#34; width=&#34;672&#34; /&gt;&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;coxph(Surv(OS, OS.EVENT) ~ TRT01P, data = dat_oak)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## Call:
## coxph(formula = Surv(OS, OS.EVENT) ~ TRT01P, data = dat_oak)
## 
##                     coef exp(coef) se(coef)      z        p
## TRT01PMPDL3280A -0.31667   0.72857  0.08418 -3.762 0.000169
## 
## Likelihood ratio test=14.16  on 1 df, p=0.0001677
## n= 850, number of events= 569&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;The z-value is -3.762 (lower is better). This should be very similar to the z-value of the log-rank test. Let’s check using a function I’ve written for my own R package &lt;a href=&#34;https://github.com/dominicmagirr/swlrt&#34;&gt;swlrt&lt;/a&gt;.&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;swlrt::wlrt(df = dat_oak,
            trt_colname = &amp;quot;TRT01P&amp;quot;,
            time_colname = &amp;quot;OS&amp;quot;,
            event_colname = &amp;quot;OS.EVENT&amp;quot;,
            wlr = &amp;quot;lr&amp;quot;)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;##           u      v_u         z o_minus_e_trt
## 1 -44.59584 139.4881 -3.775946     MPDL3280A&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;Had the non-proportional hazards been anticipated, a weighted log-rank test could have been pre-specified, for example a &lt;a href=&#34;https://onlinelibrary.wiley.com/doi/full/10.1002/sim.8186&#34;&gt;modestly-weighted log-rank test&lt;/a&gt; with &lt;span class=&#34;math inline&#34;&gt;\(t^* = 12\)&lt;/span&gt;…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;swlrt::wlrt(df = dat_oak,
            trt_colname = &amp;quot;TRT01P&amp;quot;,
            time_colname = &amp;quot;OS&amp;quot;,
            event_colname = &amp;quot;OS.EVENT&amp;quot;,
            wlr = &amp;quot;mw&amp;quot;,
            t_star = 12)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;##           u      v_u         z o_minus_e_trt
## 1 -74.88024 370.4699 -3.890368     MPDL3280A&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;This would have had a lower z-value (-3.89), as you’d expect given the slightly delayed effect,&lt;/p&gt;
&lt;div id=&#34;but-what-about-an-adjusted-analysis&#34; class=&#34;section level3&#34;&gt;
&lt;h3&gt;But what about an adjusted analysis?&lt;/h3&gt;
&lt;p&gt;Let’s look at a Cox model including ECOG grade as a covariate…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;coxph(Surv(OS, OS.EVENT) ~ TRT01P + ECOGGR, data = dat_oak)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## Call:
## coxph(formula = Surv(OS, OS.EVENT) ~ TRT01P + ECOGGR, data = dat_oak)
## 
##                     coef exp(coef) se(coef)      z        p
## TRT01PMPDL3280A -0.35234   0.70304  0.08445 -4.172 3.02e-05
## ECOGGR           0.63227   1.88187  0.09072  6.970 3.18e-12
## 
## Likelihood ratio test=65.79  on 2 df, p=5.163e-15
## n= 850, number of events= 569&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;Now the z-value is -4.172. So in this example, remembering to adjust for a prognostic covariate appears more important than dealing with the nph issue.&lt;/p&gt;
&lt;/div&gt;
&lt;div id=&#34;cant-we-do-both&#34; class=&#34;section level3&#34;&gt;
&lt;h3&gt;Can’t we do both?&lt;/h3&gt;
&lt;p&gt;Yes, it’s possible to do the modestly-weighted log-rank test, stratified by ECOG grade:&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;swlrt::swlrt(df = dat_oak,
             trt_colname = &amp;quot;TRT01P&amp;quot;,
             time_colname = &amp;quot;OS&amp;quot;,
             event_colname = &amp;quot;OS.EVENT&amp;quot;,
             strat_colname = &amp;quot;ECOGGR&amp;quot;,
             wlr = &amp;quot;mw&amp;quot;,
             t_star = 12)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## $by_strata
##                 u       v_u         z o_minus_e_trt
## ECOGGR0 -15.46822  87.47411 -1.653867     MPDL3280A
## ECOGGR1 -71.10216 307.90543 -4.052044     MPDL3280A
## 
## $z
## [1] -4.353737&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;Now the z-value is lower still (-4.35), which seems like the best of both worlds.&lt;/p&gt;
&lt;/div&gt;
&lt;div id=&#34;will-covariate-adjustment-always-improve-the-z-value&#34; class=&#34;section level3&#34;&gt;
&lt;h3&gt;Will covariate adjustment always improve the z-value?&lt;/h3&gt;
&lt;p&gt;No. Let’s go through exactly the same steps for the POPLAR study.&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;## read in the clinical data from the POPLAR study
## create a new column OS.EVENT which is the opposite
## of OS.CNSR
dat_poplar &amp;lt;- readxl::read_excel(&amp;quot;41591_2018_134_MOESM3_ESM.xlsx&amp;quot;,
                              sheet = 2) %&amp;gt;% 
  select(PtID, ECOGGR, OS, OS.CNSR, TRT01P) %&amp;gt;%
  mutate(OS.EVENT = -1 * (OS.CNSR - 1))


km_poplar &amp;lt;- survfit(Surv(OS, OS.EVENT) ~ TRT01P,
                  data = dat_poplar)

survminer::ggsurvplot(km_poplar, 
                      data = dat_poplar, 
                      risk.table = TRUE, 
                      break.x.by = 6,
                      legend.title = &amp;quot;&amp;quot;,
                      xlab = &amp;quot;Time (months)&amp;quot;,
                      ylab = &amp;quot;Overall survival&amp;quot;,
                      risk.table.fontsize = 4,
                      legend = c(0.8,0.8))&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;&lt;img src=&#34;../../post/2020-09-12-adjusting-for-covariates-under-non-proportional-hazards_files/figure-html/unnamed-chunk-7-1.png&#34; width=&#34;672&#34; /&gt;&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;coxph(Surv(OS, OS.EVENT) ~ TRT01P, data = dat_poplar)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## Call:
## coxph(formula = Surv(OS, OS.EVENT) ~ TRT01P, data = dat_poplar)
## 
##                    coef exp(coef) se(coef)      z       p
## TRT01PMPDL3280A -0.3928    0.6752   0.1426 -2.754 0.00589
## 
## Likelihood ratio test=7.64  on 1 df, p=0.005724
## n= 287, number of events= 200&lt;/code&gt;&lt;/pre&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;coxph(Surv(OS, OS.EVENT) ~ TRT01P + ECOGGR, data = dat_poplar)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## Call:
## coxph(formula = Surv(OS, OS.EVENT) ~ TRT01P + ECOGGR, data = dat_poplar)
## 
##                    coef exp(coef) se(coef)      z       p
## TRT01PMPDL3280A -0.3770    0.6859   0.1426 -2.644 0.00819
## ECOGGR           0.4501    1.5684   0.1587  2.836 0.00457
## 
## Likelihood ratio test=16.18  on 2 df, p=0.000306
## n= 287, number of events= 200&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;In this case the z-value from the unadjusted Cox model is -2.75, whereas adjusting for ECOGGR it’s -2.644. Let’s look at the un-stratified and stratified modestly-weighted logrank tests (&lt;span class=&#34;math inline&#34;&gt;\(t^* = 12\)&lt;/span&gt;)…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;## unstratified
swlrt::wlrt(df = dat_poplar,
            trt_colname = &amp;quot;TRT01P&amp;quot;,
            time_colname = &amp;quot;OS&amp;quot;,
            event_colname = &amp;quot;OS.EVENT&amp;quot;,
            wlr = &amp;quot;mw&amp;quot;,
            t_star = 12)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;##           u      v_u         z o_minus_e_trt
## 1 -36.83455 134.8164 -3.172372     MPDL3280A&lt;/code&gt;&lt;/pre&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;## stratified
swlrt::swlrt(df = dat_poplar,
             trt_colname = &amp;quot;TRT01P&amp;quot;,
             time_colname = &amp;quot;OS&amp;quot;,
             event_colname = &amp;quot;OS.EVENT&amp;quot;,
             strat_colname = &amp;quot;ECOGGR&amp;quot;,
             wlr = &amp;quot;mw&amp;quot;,
             t_star = 12)&lt;/code&gt;&lt;/pre&gt;
&lt;pre&gt;&lt;code&gt;## $by_strata
##                 u       v_u         z o_minus_e_trt
## ECOGGR0 -12.98698  27.30791 -2.485215     MPDL3280A
## ECOGGR1 -20.73634 114.79982 -1.935359     MPDL3280A
## 
## $z
## [1] -2.828926&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;Same pattern here, but with lower z-values, as you’d expect given the delayed effect.&lt;/p&gt;
&lt;/div&gt;
&lt;div id=&#34;why-the-different-behaviour-oak-vs-poplar&#34; class=&#34;section level3&#34;&gt;
&lt;h3&gt;Why the different behaviour: OAK vs POPLAR?&lt;/h3&gt;
&lt;p&gt;This is partly explained from looking at the KM curves by ECOG grade in the two studies. In OAK there is a very big difference in surival (ECOG 1 vs ECOG 0) with the median more-or-less doubling…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;km_oak_ecog &amp;lt;- survfit(Surv(OS, OS.EVENT) ~ ECOGGR,
                       data = dat_oak)

survminer::ggsurvplot(km_oak_ecog, 
                      data = dat_oak, 
                      risk.table = TRUE, 
                      break.x.by = 6,
                      legend.title = &amp;quot;&amp;quot;,
                      xlab = &amp;quot;Time (months)&amp;quot;,
                      ylab = &amp;quot;Overall survival&amp;quot;,
                      risk.table.fontsize = 4,
                      legend = c(0.8,0.8))&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;&lt;img src=&#34;../../post/2020-09-12-adjusting-for-covariates-under-non-proportional-hazards_files/figure-html/unnamed-chunk-9-1.png&#34; width=&#34;672&#34; /&gt;&lt;/p&gt;
&lt;p&gt;…whereas for POPLAR there is still a clear difference but median only increased by about 33%…&lt;/p&gt;
&lt;pre class=&#34;r&#34;&gt;&lt;code&gt;km_poplar_ecog &amp;lt;- survfit(Surv(OS, OS.EVENT) ~ ECOGGR,
                          data = dat_poplar)


survminer::ggsurvplot(km_poplar_ecog, 
                      data = dat_poplar, 
                      risk.table = TRUE, 
                      break.x.by = 6,
                      legend.title = &amp;quot;&amp;quot;,
                      xlab = &amp;quot;Time (months)&amp;quot;,
                      ylab = &amp;quot;Overall survival&amp;quot;,
                      risk.table.fontsize = 4,
                      legend = c(0.8,0.8))&lt;/code&gt;&lt;/pre&gt;
&lt;p&gt;&lt;img src=&#34;../../post/2020-09-12-adjusting-for-covariates-under-non-proportional-hazards_files/figure-html/unnamed-chunk-10-1.png&#34; width=&#34;672&#34; /&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div id=&#34;conclusions&#34; class=&#34;section level3&#34;&gt;
&lt;h3&gt;Conclusions&lt;/h3&gt;
&lt;p&gt;This is just a couple of quick examples, but I think it’s safe to say that if you believe you have a strong prognostic covariate and a delayed treatment effect, then a stratified modestly-weighted logrank test is likely to be a good option in terms of type 1 error and power.&lt;/p&gt;
&lt;p&gt;A lot of work has been done on covariate adjustment. Clearly, it’s a complex discussion but I think the consensus is that you are likely to gain more than you lose. A few references I’ve found useful:&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.sciencedirect.com/science/article/pii/S0197245697001475&#34; class=&#34;uri&#34;&gt;https://www.sciencedirect.com/science/article/pii/S0197245697001475&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://www.sciencedirect.com/science/article/pii/S1047279705003248&#34; class=&#34;uri&#34;&gt;https://www.sciencedirect.com/science/article/pii/S1047279705003248&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-139&#34; class=&#34;uri&#34;&gt;https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-139&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href=&#34;https://onlinelibrary.wiley.com/doi/full/10.1002/sim.5713&#34; class=&#34;uri&#34;&gt;https://onlinelibrary.wiley.com/doi/full/10.1002/sim.5713&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;The stratified weighted log-rank test has its limits. It can’t handle continuous covariates, and it’s going to break down when the number of strata becomes too large.&lt;/p&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>Non-proportional hazards in immuno-oncology: is an old perspective needed?</title>
      <link>/post/non-proportional-hazards-in-immuno-oncology-is-an-old-perspective-needed/</link>
      <pubDate>Fri, 10 Jul 2020 00:00:00 +0000</pubDate>
      <guid>/post/non-proportional-hazards-in-immuno-oncology-is-an-old-perspective-needed/</guid>
      <description>


&lt;p&gt;In my opinion, many phase III trials in immuno-oncology are 10–20 % larger than they need (ought) to be.&lt;/p&gt;
&lt;p&gt;This is because the method we use for the primary analysis doesn’t match what we know about how these drugs work.&lt;/p&gt;
&lt;p&gt;Fixing this doesn’t require anything fancy, just old-school stats from the 1960s.&lt;/p&gt;
&lt;p&gt;In this &lt;a href=&#34;https://arxiv.org/abs/2007.04767&#34;&gt;new preprint&lt;/a&gt; I try to explain how I think it should be done.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Is there still a place for significance testing in clinical trials?</title>
      <link>/post/is-there-still-a-place-for-significance-testing-in-clinical-trials/</link>
      <pubDate>Sun, 26 Apr 2020 00:00:00 +0000</pubDate>
      <guid>/post/is-there-still-a-place-for-significance-testing-in-clinical-trials/</guid>
      <description>


&lt;p&gt;I’ve spent a lot of time thinking about hypothesis tests in clinical trials recently. Periodically, it’s good to question the fundamentals of whether this is a good idea in general. I don’t think my views have changed. I was considering writing a blog post but then I came across &lt;a href=&#34;https://ora.ox.ac.uk/objects/uuid:95a357f2-5ba2-4563-aeb6-ccdfdc031360/download_file?file_format=pdf&amp;amp;safe_filename=Cook_etal_2019_There_is_still_a_place.pdf&amp;amp;type_of_work=Journal+article&#34;&gt;this article&lt;/a&gt; by the editors of the Clinical Trials journal which pretty much sums it up. The article can also be found with DOI: 10.1177/1740774519846504.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
